nan
Artificial Intelligence (AI)-Enabled Battlefield Management And Decision Support Systems Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The non-opioid pain management market has experienced robust expansion over the past few years. The market is projected to expand from $44.93 billion in 2025 to $48.78 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.6%. Historically, this growth can be ascribed to several factors, including heightened awareness concerning opioid addiction dangers, a rise in the incidence of chronic pain conditions, wider acceptance of non-opioid pain relievers, the proliferation of hospital-based pain management initiatives, and the increased application of physical therapy and rehabilitation methods.
The non-opioid pain management market is projected to experience substantial expansion over the coming years. Its valuation is anticipated to reach $68.34 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.8%. This growth during the forecast period is fueled by factors such as the increasing embrace of AI-powered tools for pain assessment, greater investment in personalized medicine and genomics, the broadening scope of digital health and remote patient monitoring, a surge in demand for non-invasive and drug-free treatments, and the integration of wearable and connected healthcare devices. Key trends expected in this period include the rising acceptance of diverse non-opioid therapies that blend pharmacological and physical approaches, wider deployment of digital therapeutics for managing and tracking chronic pain, a stronger inclination towards tailored pain treatment plans based on individual patient profiles, the development of less invasive and regenerative pain relief methods, and greater incorporation of wearable technologies for real-time pain tracking and support in rehabilitation.
Download A Free Sample Report For Comprehensive Market Insights:
Non-Opioid Pain Management Market Growth Drivers: What Factors Are Accelerating Expansion?
The increasing occurrence of chronic pain conditions is anticipated to fuel the expansion of the non-opioid pain management market in the future. These conditions are defined as ailments characterized by persistent or recurrent pain extending beyond three months, which can significantly impair daily activities and overall quality of life. The growth in the aging population is contributing to the rise in chronic pain conditions, given that older individuals are more susceptible to experiencing prolonged pain stemming from age-related issues affecting their musculoskeletal system and nerves. Non-opioid pain management offers a solution for chronic pain conditions by alleviating ongoing pain and inflammation, simultaneously enhancing mobility and functional capabilities, all without the risk of dependence linked to opioid drugs. An illustrative example is the estimate by Arthritis Australia, an Australia-based non-profit organization, that by February 2025, around 5.39 million Australians will be affected by arthritis, marking a 31% rise since 2025. Consequently, the escalating occurrence of chronic pain conditions is fostering the expansion of the non-opioid pain management market.
Artificial Intelligence (AI)-Enabled Battlefield Management And Decision Support Systems Market Segment Analysis Highlighting Growth Areas
The non-opioid pain management market covered in this report is segmented –
1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs; Antidepressants; Local Anesthetics; Anticonvulsants; Other Drug Classes
2) By Indication: Chronic Pain; Acute Pain
3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Pharmacies
4) By Application: Neuropathic Pain; Musculoskeletal Pain; Cancer Pain; Post-Operative Pain; Migraine
5) By End User: Hospitals; Clinics; Ambulatory Surgical Centers; Rehabilitation Centers; Home Care Settings
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs: Ibuprofen; Naproxen; Diclofenac
2) By Antidepressants: Tricyclic Antidepressants; Serotonin-Norepinephrine Reuptake Inhibitors; Selective Serotonin Reuptake Inhibitors
3) By Local Anesthetics: Lidocaine; Bupivacaine; Ropivacaine
4) By Anticonvulsants: Gabapentin; Pregabalin; Carbamazepine
5) By Other Drug Classes: Muscle Relaxants; Capsaicin Based Therapies; Cannabinoid Based Therapies
Innovative Non-Opioid Oral Analgesics Enhance Safe And Effective Acute Pain Management
Major companies operating in the non-opioid pain management market are focusing on developing innovative solutions, such as non-opioid oral analgesics, to provide effective pain relief with reduced risk of addiction and fewer side effects compared to opioid-based therapies. Non-opioid oral analgesics are orally administered pain-relief medications used to manage mild to moderate pain without opioid compounds, helping reduce the risk of dependence while effectively treating conditions such as headaches, arthritis, musculoskeletal disorders, and post-operative pain. For instance, in January 2025, Vertex Pharmaceuticals Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic indicated for the treatment of moderate to severe acute pain in adults. The therapy works by selectively targeting NaV1.8 sodium channels in the peripheral nervous system, helping block pain signals before they reach the brain. This approval marked a significant advancement in non-opioid pain management by providing an effective alternative to opioid-based therapies.
Non-Opioid Pain Management Market Key Players And Strategic Industry Positioning
Major companies operating in the non-opioid pain management market are Johnson & Johnson; Pfizer Inc.; Bayer AG; Abbott Laboratories; Eli Lilly and Company; Boehringer Ingelheim; Teva Pharmaceutical Industries Ltd.; Haleon plc; Sun Pharmaceutical Industries Ltd.; Vertex Pharmaceuticals Incorporated; Perrigo Company plc; Aurobindo Pharma; Cipla Ltd.; Lupin Limited; Amneal Pharmaceuticals; Zydus Lifesciences; Pacira BioSciences Inc.; Alvogen; Heron Therapeutics; Hyloris Pharmaceuticals; Pierrel S.p.A.; Regenexbio.
Access The Complete Non-Opioid Pain Management Market Report:
Non-Opioid Pain Management Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the non-opioid pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-opioid pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.